Skip to Main Content

Paper Details

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF<sup>V600E</sup> colorectal tumors.
Nat Cancer
12
2023
-, BRAF, BRAF CRC, BRAF colorectal tumors, BRAFEGFR, COX2, CRC, CTNNB1, EGFR, ERK, MEK, SRC, SRC kinases, catenin, cyclooxygenase-2, metastatic colorectal cancer, patient, prostaglandin E, tumor
Author NameAffiliation
Denise P Mu??ozHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Danislav S SpassovHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Danislav S SpassovFaculty of Pharmacy, Medical University of Sofia
Denise M WolfHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Scott R VandenBergHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Scott R VandenBergHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Kevan M ShokatHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Mark M MoasserHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Jorge Silvio GutkindUniversity of California
Jorge Silvio GutkindMoores Cancer Center, University of California
Laura J Van't VeerHelen Diller Family Comprehensive Cancer Center, University of California san francisco
  • 1 - 11

Datasets